Lean NAFLD: an Underrecognized and Challenging Disorder in Medicine

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2021 Jan 3

PMID 33389543

Citations 39

Authors

Sheila Maier

Amanda Wieland

Melanie Cree-Green

Kristen Nadeau

Shelby Sullivan

Miguel A Lanaspa

Richard J Johnson

Thomas Jensen

Affiliations

Soon will be listed here.

Abstract

Classically, Non-Alcoholic Fatty Liver Disease (NAFLD) has been thought to be driven by excessive weight gain and obesity. The overall greater awareness of this disorder has led to its recognition in patients with normal body mass index (BMI). Ongoing research has helped to better understand potential causes of Lean NAFLD, the risks for more advanced disease, and potential therapies. Here we review the recent literature on prevalence, risk factors, severity of disease, and potential therapeutic interventions.

Citing Articles

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.

The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study.

He Q, Liu X, Ding G, Wang Y, Luo X, Cao W BMC Public Health. 2025; 25(1):718.

PMID: 39984884 PMC: 11843771. DOI: 10.1186/s12889-025-21943-w.

Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet.

Arivazhagan L, Delbare S, Wilson R, Manigrasso M, Zhou B, Ruiz H JHEP Rep. 2025; 7(2):101222.

PMID: 39911943 PMC: 11795143. DOI: 10.1016/j.jhepr.2024.101222.

Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.

Njei B, Ameyaw P, Al-Ajlouni Y, Njei L, Boateng S Cureus. 2024; 16(10):e71451.

PMID: 39544615 PMC: 11560387. DOI: 10.7759/cureus.71451.

Thiostrepton: multifaceted biological activities and its applications in treatment of inflammatory diseases.

Asikaer A, Sun C, Shen Y Inflammopharmacology. 2024; 33(1):183-194.

PMID: 39487942 DOI: 10.1007/s10787-024-01587-9.

References

Wei J, Leung J, Loong T, Wong G, Yeung D, Chan R . Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol. 2015; 110(9):1306-14. DOI: 10.1038/ajg.2015.235. View

Williams C, Oxon B, Lond H . Kwashiorkor: a nutritional disease of children associated with a maize diet. 1935. Bull World Health Organ. 2004; 81(12):912-3. PMC: 2572388. View

Pingitore P, Romeo S . The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1864(6):900-906. DOI: 10.1016/j.bbalip.2018.06.018. View

Lanaspa M, Ishimoto T, Li N, Cicerchi C, Orlicky D, Ruzycki P . Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun. 2013; 4:2434. PMC: 3833672. DOI: 10.1038/ncomms3434. View

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

Luukkonen P, Tukiainen T, Juuti A, Sammalkorpi H, Haridas P, Niemela O . Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight. 2020; 5(5). PMC: 7141400. DOI: 10.1172/jci.insight.132158. View

Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette J, Diehl A . Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48(6):993-9. PMC: 2423467. DOI: 10.1016/j.jhep.2008.02.011. View

Ishimoto T, Lanaspa M, Rivard C, Roncal-Jimenez C, Orlicky D, Cicerchi C . High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology. 2013; 58(5):1632-43. PMC: 3894259. DOI: 10.1002/hep.26594. View

Thiagarajan P, Aithal G . Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol. 2019; 9(4):515-521. PMC: 6728526. DOI: 10.1016/j.jceh.2019.03.002. View

10.

Feldman A, Eder S, Felder T, Kedenko L, Paulweber B, Stadlmayr A . Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2016; 112(1):102-110. DOI: 10.1038/ajg.2016.318. View

11.

Jensen T, Abdelmalek M, Sullivan S, Nadeau K, Green M, Roncal C . Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018; 68(5):1063-1075. PMC: 5893377. DOI: 10.1016/j.jhep.2018.01.019. View

12.

Adejumo A, Alliu S, Ajayi T, Adejumo K, Adegbala O, Onyeakusi N . Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. PLoS One. 2017; 12(4):e0176416. PMC: 5404771. DOI: 10.1371/journal.pone.0176416. View

13.

Kumarendran B, OReilly M, Manolopoulos K, Toulis K, Gokhale K, Sitch A . Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Med. 2018; 15(3):e1002542. PMC: 5873722. DOI: 10.1371/journal.pmed.1002542. View

14.

Selvakumar P, Nasser Kabbany M, Lopez R, Rayas M, Lynch J, Alkhouri N . Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Lean Adolescents in the United States. J Pediatr Gastroenterol Nutr. 2018; 67(1):75-79. DOI: 10.1097/MPG.0000000000001974. View

15.

Honda Y, Yoneda M, Kessoku T, Ogawa Y, Tomeno W, Imajo K . Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors. Hepatol Res. 2016; 46(10):1011-8. DOI: 10.1111/hepr.12648. View

16.

Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D . What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int. 2020; 40(6):1254-1261. DOI: 10.1111/liv.14478. View

17.

Bertot L, Adams L . The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016; 17(5). PMC: 4881593. DOI: 10.3390/ijms17050774. View

18.

Younossi Z, Ratziu V, Loomba R, Rinella M, Anstee Q, Goodman Z . Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019; 394(10215):2184-2196. DOI: 10.1016/S0140-6736(19)33041-7. View

19.

Cotrim H, de Freitas L, Freitas C, Braga L, Sousa R, Carvalho F . Clinical and histopathological features of NASH in workers exposed to chemicals with or without associated metabolic conditions. Liver Int. 2004; 24(2):131-5. DOI: 10.1111/j.1478-3231.2004.0897.x. View

20.

El Hadi H, Vettor R, Rossato M . Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?. Antioxidants (Basel). 2018; 7(1). PMC: 5789322. DOI: 10.3390/antiox7010012. View